Oncolytics: pelareorep shows 15-month response in anal cancer

Oncolytics Biotech has reported updated data from Cohort 4 of its Phase 1/2 GOBLET study, showing a median duration of response of approximately 15 months for pelareorep combined with atezolizumab in patients with second-line or later squamous cell anal cancer. The NASDAQ-listed company said all patients who responded to treatment survived beyond one year, with several exceeding two years. Median overall survival had not yet been reached at the time of the data cut.

The result compares favourably with the 9.5-month median duration of response reported for retifanlimab monotherapy, an FDA-approved second-line checkpoint inhibitor in a comparable patient population, according to a 2020 study published in the Annals of Oncology. Oncolytics has been careful to note that the comparison is historical rather than head-to-head, and that the GOBLET data derive from internal calculations rather than a peer-reviewed publication.

Regulatory path

The company said it has received FDA Fast Track Designation for pelareorep in anal cancer and has had recent regulatory interactions that it describes as providing clarity on a potential registrational path. Oncolytics believes durable response data could support an application for accelerated approval, with overall survival data potentially underpinning a subsequent full approval, subject to FDA agreement. The company intends to seek a checkpoint inhibitor partner to co-develop a registration-directed study.

Chief executive Jared Kelly said the anal cancer data serve as a foundation for a broader strategy targeting HPV-driven tumours. "Our survival data and recent FDA regulatory clarity give us a path to pursue registration in anal cancer while expanding into other HPV-associated tumors, including head and neck cancer, where pelareorep has already demonstrated encouraging clinical activity," he said.

More than 90% of squamous cell anal cancer cases are associated with human papillomavirus infection, and the company says HPV accounts for roughly 70% of oropharyngeal cancers in the United States, a large patient population in which checkpoint inhibitors are already standard of care. Oncolytics said it is considering initiating a combination study of pelareorep plus a checkpoint inhibitor in head and neck squamous cell carcinoma, though no trial has been announced.

Market context

Oncolytic virotherapy occupies a distinctive, if still largely unvalidated at scale, position within the immuno-oncology landscape. Pelareorep is a double-stranded RNA reovirus that Oncolytics says selectively replicates in tumour cells while stimulating both innate and adaptive immune responses, a dual mechanism the company argues makes it well suited as a combination partner for checkpoint inhibitors. The drug has now been administered to more than 1,200 patients across multiple tumour types, including pancreatic and colorectal cancer studies within the GOBLET programme.

The HPV-driven cancer platform thesis is strategically coherent: shared viral aetiology and existing checkpoint inhibitor approval in head and neck cancer could allow clinical learnings to translate across indications. However, the company has yet to announce a partnership for the registrational path it is describing, and will need to secure one to fund a pivotal study. Investors will be watching for partnership announcements and a named registrational study design as the key near-term catalysts.